|
It was reported that dissection occurred, requiring additional intervention.On (b)(6) 2026, the subject underwent treatment with the eluvia drug-eluting stent as part of the clinical trial.The target lesion #001 was located in the right mid superficial femoral artery, with a proximal reference vessel diameter of 6 mm and distal reference vessel diameter of 6 mm, a lesion length of 290 mm, and 95% stenosis, and was classified as a trans-atlantic inter-society consensus (tasc ii) c lesion.Prior to treatment with the study devices, pre-dilation was performed using a 5 mm x 220 mm sterling otw pta balloon.Treatment of the target lesion was performed using 6 mm x 150 mm and 6 mm x 120 mm eluvia drug-eluting stents, followed by dilation with a 5 mm x 40 mm ranger drug-coated balloon.Following treatment, post-dilation was performed using a 6 mm x 150 mm sterling otw pta balloon, and the final residual stenosis was noted to be 0%.On (b)(6) 2026, during treatment of the target lesion, a grade d dissection was noted in the right mid superficial femoral artery.The site confirmed that the 5 mm x 220 mm sterling otw pta balloon was associated with the dissection.In response to the event, a bailout stent was placed, and the final residual stenosis was 0%.The dissection was considered resolved on (b)(6) 2026, and the subject was discharged from the hospital on the same day on dual antiplatelet therapy.
|
|
Detailed product information was not provided to bsc.We completed a good faith effort to obtain the information.Because the product is unknown at this time, we are unable to provide the complete unique identifier (udi) # and other specific product information.If additional details become available, a supplemental report will be submitted.
|